CDMOs announced expansions, exhibitors showcased automated equipment, and supply chain strategy discussions were a focus at CPHI Milan 2026.
|Articles|August 1, 2001
- Pharmaceutical Technology-08-01-2001
- Volume 2001 Supplement
- Issue 2
Successfully Outsourcing Formulation DevelopmentConsiderations for Emerging Biopharmaceutical Companies
Author(s)Shabbir T. Anik, PhD, Colin M. Minchom, PhD
Successfully taking a new chemical entity from proof-of-concept to commercialization requires the biopharmaceutical company to carefully evaluate a contract services provider's formulation department and ability to become a fully integrated supplier.
Advertisement
Articles in this issue
over 25 years ago
Creating a Successful Partnership with a Contract Manufacturerover 25 years ago
Outsourcing Outlookover 25 years ago
Creative Solutions in Client-CRO Relationshipsover 25 years ago
Third-Party Technology Transferover 25 years ago
The Squeeze in Contract Manufacturingover 25 years ago
Stakes Rise for Blown Batchesover 25 years ago
Partnerships in Drug DiscoveryAdvertisement
Related to this article
Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Drapeau’s AI Deep Dive: The Price of Acceptance in Regulated AI
2
Improving Oral Peptide Delivery Through Structural Modifications
3
Regulatory Roundup—October 2026: FDA Advances Rare Disease Development and Transparency Efforts
4
Using OEE Monitoring to Justify Expenditure on Aging Production Lines
5